- Companies
- Benchling
Benchling Revenue, Valuation, Funding & Investors
Benchling is valued at $6.1B as of November 2021, a 29.0x multiple on its last reported $210M revenue.
Last Benchling valuation
$6.1B
Series F · Nov 2021
Last Benchling funding round
$100M
Series F · Nov 2021
Benchling revenue
$210M
Series F · Nov 2021
Key investors in Benchling
Thrive Capital
Benchmark
Menlo Ventures
Y Combinator
Andreessen Horowitz
Lux Capital
About Benchling
Benchling is a San Francisco-headquartered cloud platform for biotech R&D launched in 2012 that supports molecular biology workflows including DNA design, CRISPR editing, and experiment tracking. Adopted by Pfizer, Regeneron, and Moderna for vaccine development, it serves over 200,000 scientists at more than 3,000 organizations worldwide.
Founded
2012
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Revenue
$210M (Nov 2021)
Valuation
$6.1B (Nov 2021)
Benchling Valuation
Benchling is currently valued at $6.1B, based on its Series F in November 2021.
The $100M round was led by Altimeter Capital and Putnam Premier IT, with participation from Lone Pine Capital.
Benchling's valuation has grown 7.2x from $850M at its Series D in May 2020 to $6.1B in November 2021, across 3 priced rounds.
Benchling valuation by funding round
Revenue multiple| Date | Stage | Valuation | Revenue Multiple |
|---|---|---|---|
| Nov 2021 | Series F | $6.1B | 29.0x |
| Apr 2021 | Series E | $4B | 80.0x |
| May 2020 | Series D | $850M | 4.0x |
Benchling Revenue
Benchling's latest recorded revenue is $210M, as of its Series F in November 2021. At a $6.1B valuation, that implies a 29.0x revenue multiple.
Revenue moved from $210M in May 2020 to $210M in November 2021, while the revenue multiple moved from 4.0x to 29.0x.
Benchling revenue by funding round
| Date | Revenue * | Valuation | Revenue Multiple | Stage |
|---|---|---|---|---|
| Nov 2021 | $210M | $6.1B | 29.0x | Series F |
| Apr 2021 | $50M | $4B | 80.0x | Series E |
| May 2020 | $210M | $850M | 4.0x | Series D |
* Revenue (or ARR) figures are the values recorded alongside each funding round. Typically run-rate revenue at the time of the deal, or a reported LTM (last 12 months) revenue.
Benchling Funding History
Benchling has raised a total of $412M across 8 funding rounds.
Benchling's first fundraising round was a $900K seed round in February 2014. The most recent completed round was a $100M Series F in November 2021.
Benchling funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Nov 2021 | Series F | Altimeter Capital (lead); Putnam Premier IT (lead); Lone Pine Capital | $100M | $6.1B | Benchling is a leading life sciences R&D cloud platform that provides software for biotech companies to digitize scientific processes, centralize data, and accelerate research in areas like biopharmaceuticals, agriculture, and therapeutics development. The platform supports lab automation, data visualization, and enterprise-scale deployments, serving customers including Gilead Sciences, Sanofi, Regeneron, and over 90 in EMEA by late 2021. In November 2021, Benchling raised $100 million in a Series F round co-led by Altimeter Capital and Franklin Templeton (noted as Putnam Premier IT in some contexts), at a $6 billion pre-money valuation, following a $200 million Series E in April 2021. The funding was aimed at expanding product development, such as capabilities for early development and RNA therapeutics, and growing its global footprint, particularly in EMEA where it had rapidly scaled to over 60 team members. At the time of the Series F, Benchling reported triple-digit year-over-year revenue growth in its most recent fiscal quarter, a 70% increase in customer count, and a 169% dollar-based net expansion rate from upsells within existing accounts. Earlier in April 2021, the company had doubled its ARR for the fourth straight year, adding over 150 customers. Benchling's traction included 99% customer retention, 52% average expansion per customer in 2020, and 43% of new revenue from the top 50 life sciences firms. The company had raised approximately $400 million total by late 2021 across multiple rounds. |
| Apr 2021 | Series E | Sequoia Capital (lead); ICONIQ Capital; Menlo Ventures; Lead Edge Capital; Spark Capital; Lux Capital; Byers Capital; Benchmark; Altimeter Capital; Thrive Capital; Alkeon Capital | $200M | $4B | Benchling, a San Francisco-based life sciences R&D cloud platform, provides cloud-based software that enables scientists in biotech, biopharma, agriculture, and other industries to track findings, collaborate, and accelerate research and development processes. The platform supported Covid-19 antibody treatments and serves over 150 enterprises, 300,000 scientists, and 1,000 R&D organizations across medicine, agriculture, materials, food, consumer packaged goods, and energy. On April 14, 2021, Benchling raised $200 million in its Series E funding round, achieving a $4 billion post-money valuation and unicorn status. The round was led by Sequoia Capital Global Equities, with participation from Altimeter Capital, Byers Capital, Elad Gil, and existing investors including Thrive Capital, Benchmark, Menlo Ventures, Alkeon Capital, ICONIQ, Lux Capital, Spark Capital, and Lead Edge Capital. This brought total funding to approximately $350 million, positioning the company closer to an IPO. Benchling's revenue exceeded $50 million in 2020, doubling from 2019, with annual recurring revenue (ARR) doubling for the fourth consecutive year. The funds were earmarked for aggressive investment in product development, global expansion, and supporting enterprise customers in therapeutic research verticals. The Series E followed a $50 million Series D in 2020 led by Alkeon Capital. A subsequent Series F round in November 2021 raised $100 million at a $6.1 billion valuation, co-led by Altimeter Capital and Franklin Templeton, with new investors Tiger Global and Lone Pine Capital, to further product development and EMEA expansion. |
| May 2020 | Series D | Alkeon Capital (lead); ICONIQ Capital; Menlo Ventures; Spark Capital; Lux Capital; Benchmark; Thrive Capital | $50M | $850M | Benchling is a life sciences R&D cloud platform that provides end-to-end software for biotech companies to manage research, development, collaboration, and data. It serves scientists at organizations developing therapeutics, sustainable products, and more, with customers including Gilead and Sanofi. The platform supports advanced product capabilities and international expansion. On May 28, 2020, Benchling closed a $50 million Series D funding round led by Alkeon Capital, with participation from new investors Spark Capital, Lux Capital, and ICONIQ Partners, plus existing investors Benchmark, Thrive Capital, and Menlo Ventures. CEO Saji Wickramasekara told Forbes the round brought total funding to $114 million at an $850 million valuation. The capital was intended to develop advanced product capabilities and expand international presence, including opening an office in Zurich, Switzerland. In 2020, Benchling doubled its annual recurring revenue and added over 150 new users amid the COVID-19 pandemic. By the following year, revenue exceeded $50 million, doubling from the prior year. The company continued raising capital, with a $200 million Series E in April 2021 at $4 billion valuation led by Sequoia Capital Global Equities, and later rounds including Series F. |
| Jul 2019 | Series C | Menlo Ventures (lead); Y Combinator; Lead Edge Capital; Benchmark; Thrive Capital | $35M | - | Benchling is a life sciences R&D cloud platform that provides software for managing biotech research workflows, replacing traditional pen-and-paper processes with a unified system of record. The company raised $34.5 million in Series C funding led by Menlo Ventures in June 2019, according to press releases. By January 2021, approximately 18 months after the Series C round, Benchling had doubled its ARR for the fourth consecutive year and surpassed 1,000 R&D organizations as customers, with over 270,000 scientists adopting the platform. The company maintained a greater than 99 percent retention rate and achieved 130 percent revenue growth in existing customers during the period preceding the Series C announcement. Benchling's funding trajectory included $7 million in Series A (October 2016), $14.5 million in Series B (June 2018), and $50 million in Series D (May 2020), demonstrating accelerating investor confidence in the platform's market traction and expansion potential within the life sciences sector. |
| Jun 2018 | Series B | Benchmark (lead); F-Prime; Thrive Capital | $15M | - | Benchling, a data management and collaboration platform for life sciences research, closed a $14.5 million Series B funding round on June 14, 2018, led by Benchmark with participation from F-Prime Capital and Thrive Capital. Benchmark General Partner Eric Vishria joined the board of directors. The funding supports accelerated product development, team growth, and expansion of its customer base among pharmaceutical, biotech, and academic users including Regeneron Pharmaceuticals, Incyte, Editas Medicine, Agenus, Zymergen, Obsidian Therapeutics, Harvard, MIT, UC Berkeley, and Stanford. At the time, over 100,000 scientists used the platform across enterprises and academia. The company reported 500% year-over-year ARR growth and a tripling of its customer base since its prior 2016 round. |
| Oct 2016 | Series A | Thrive Capital (lead); Andreessen Horowitz; Section Partners | $7M | - | Benchling, a cloud-based R&D software platform for life sciences including lab notebooks, LIMS, and molecular biology tools, raised $7 million in funding on October 24, 2016, led by Thrive Capital with participation from Andreessen Horowitz and angels including Y Combinator's Geoff Ralston, Sequoia's Matt Huang, Tencent's David Wallerstein, and Ashton Kutcher. This brought total funding to over $13 million. The platform served over 40,000 scientists across more than 10,000 academic institutions and 150 companies. Funds were allocated to expand scientific operations, broaden development into more therapeutic areas, and enhance the platform's comprehensiveness, with a planned release bridging structured and unstructured scientific data. Thrive Capital investor Miles Grimshaw highlighted Benchling's potential as leading collaboration software for researchers, akin to Greenhouse and GitHub in other sectors. |
| Apr 2015 | Seed | Andreessen Horowitz (lead); Kevin Mahaffey; Natalie Carnegie; Thrive Capital; Rogue Capital | $5M | - | - |
| Feb 2014 | Seed | SV Angel; Y Combinator; Founders Fund; Draper Associates | $900K | - | - |
Who has invested in Benchling?
23 investors have backed Benchling across its funding rounds, including Thrive Capital, Benchmark, Menlo Ventures, Y Combinator, Andreessen Horowitz and Lux Capital.
Lead investors include Altimeter Capital, Putnam Premier IT, Sequoia Capital, Alkeon Capital, Menlo Ventures and 3 other investors.
Benchling Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 6 | Lead | Apr 2015 | ||
| 4 | Lead | Jun 2018 | ||
| 3 | Lead | Jul 2019 | ||
| 2 | Participant | May 2020 | ||
| 2 | Participant | Feb 2014 | ||
| 2 | Participant | Jul 2019 | ||
| 2 | Participant | May 2020 | ||
| 2 | Participant | May 2020 | ||
| 2 | Lead | Apr 2021 | ||
| 2 | Lead | Apr 2015 | ||
| 2 | Lead | May 2020 | ||
| 1 | Lead | Nov 2021 | ||
| 1 | Participant | Feb 2014 | ||
This data is available for Pro users. Sign up to see all 23 Benchling investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Benchling
Benchling has acquired 3 companies to date.
Last acquisition by Benchling was on August 20th 2025. Benchling acquired ReSync Bio for undisclosed valuation.
Latest Acquisitions by Benchling
| Description | ReSync Bio is a scientific software company supplying biopharmaceutical firms with tools to expedite drug discovery. The solutions integrate data analysis pipelines for target identification, validation, and compound screening processes. | PipeBio is a bioinformatics platform accelerating antibody discovery and optimization for biopharma developers targeting oncology and immunology therapeutics. Boston-based and launched in 2021, it offers cloud-based tools for sequence analysis, structural modeling via AlphaFold integration, and affinity maturation simulations using datasets from 10,000-plus therapeutic antibodies. PipeBio partners with contract research organizations to streamline hit-to-lead workflows, reducing design cycles by processing gigabytes of NGS data from hybridoma and phage display screens. | Overwatch Research is a developer of experimental tracking software tailored for VivoQuant users in preclinical research. The platform streamlines data management, reduces manual errors, and facilitates lab collaboration for animal model studies. Headquartered in the United States, it targets biomedical researchers conducting physiological and imaging experiments. |
| HQ Country | |||
| HQ City | San Francisco, CA | Horsens | Belfast |
| Deal Date | 20 Aug 2025 | 20 Oct 2024 | 24 Feb 2022 |
| Valuation | undisclosed | undisclosed | $585M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Benchling acquisitions and their M&A valuation multiples. Start Free Trial | |||
Benchling Competitors
Benchling competitors include listed companies like Glaukos, United Imaging, ICON plc and Schrödinger, and private ones like Doctolib and Cityblock Health.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $507M | ($157M) | $9.5B | 14.6x | ||
| Publicly listed | $2.1B | $367M | $12B | 4.8x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Publicly listed | $256M | ($96M) | $2.3B | 7.9x | ||
| Private | $400M | - | $6.4B | 16.0x | ||
| Private | - | - | $5.7B | - |
Benchling Public Comps
Benchling is still privately-owned, but its public comps include BillionToOne, Waystar, Doximity, Adaptive Biotech, M3 Inc., CCC Intelligent Solutions, Glaukos, Privia Health, Demant and Bloomage BioTechnology.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $305M | $12M | 15.8x | 11.7x | 401.1x | 75.4x | |||
| $1.1B | $390M | 5.8x | 5.2x | 16.3x | 12.3x | |||
| $645M | $229M | 6.3x | 6.2x | 17.7x | 11.9x | |||
| $277M | ($39M) | 16.7x | 16.0x | (117.9x) | 675.9x | |||
| $2.3B | $473M | 3.1x | 3.0x | 14.8x | 11.6x | |||
| $1.1B | $238M | 4.8x | 4.5x | 21.5x | 10.8x | |||
| $507M | ($157M) | 18.4x | 14.6x | (59.6x) | 166.3x | |||
| $2.1B | $44M | 1.0x | 0.9x | 50.2x | 15.3x | |||
This data is available for Pro users. Sign up to see all Benchling competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Benchling
| When was Benchling founded? | Benchling was founded in 2012. |
| Where is Benchling headquartered? | Benchling is headquartered in San Francisco, CA, United States. |
| Is Benchling publicly listed? | No, Benchling is a private, VC-backed company. |
| What is Benchling's valuation? | Benchling was last valued at $6.1B in its Series F in November 2021. |
| How much funding has Benchling raised? | Benchling has raised $412M across 8 funding rounds. |
| What was Benchling's last funding round? | Benchling's last funding round was a $100M Series F in November 2021, led by Altimeter Capital and Putnam Premier IT. |
| Who are Benchling's investors? | Benchling's investors include Thrive Capital, Benchmark, Menlo Ventures, ICONIQ Capital, Y Combinator, Lead Edge Capital, Spark Capital, Lux Capital, Altimeter Capital, Andreessen Horowitz and 13 others. |
| What is Benchling's revenue? | Benchling's latest recorded revenue is $210M (November 2021). |
| What is Benchling's revenue multiple? | Benchling's latest valuation implies a 29.0x revenue multiple ($6.1B valuation on $210M of revenue). |
| Which companies are comparable to Benchling? | Companies comparable to Benchling include Glaukos, United Imaging, ICON plc, Schrödinger, Doctolib and Cityblock Health. |
| How many companies has Benchling acquired? | Benchling has acquired 3 companies, including ReSync Bio, PipeBio and Overwatch Research. |
| What was the largest acquisition by Benchling? | The $585M acquisition of Overwatch Research in February 2022 is the largest acquisition Benchling has made to date. |
See companies similar to Benchling
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




